Roche's star MS medicine Ocrevus wins EU approval

ZURICH (Reuters) - The European Union approved Roche's multiple sclerosis medicine Ocrevus, one the Swiss company's key new drugs that likely neared $1 billion in revenue in its first nine months on the U.S. market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

The objective of our study was to examine the Instrumented Timed-Up-and-Go test (ITUG) in relation to falls and FoF in PwMS. This case-control study comprised...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
In this study, we used electrophysiological and biochemical techniques to examine inhibitory neurotransmission in the CA1 region of the hippocampus in EAE. We find that tonic, GABAergic inhibition is enhanced in CA1 pyramidal cells from EAE mice. Although plasma membrane expression of the GABA transporter GAT-3 was decreased in the EAE hippocampus, an increased surface expression of α5 subunit-containing GABAA receptors appears to be primarily responsible for the increase in tonic inhibition during EAE. Enhanced tonic inhibition during EAE was associated with decreased CA1 pyramidal cell excitability and inhibition o...
Source: Neuroscience - Category: Neuroscience Source Type: research
Authors: Castillo-Álvarez F, Marzo-Sola ME Abstract In recent years there has been a revolution regarding the role of the microbiota in different diseases, most of them within the spectrum of inflammatory and autoimmune diseases, associated with the development of metagenomics and the concept of holobiont, a large organism together with its microbiota. Specifically, in Multiple Sclerosis, multiple evidence points to the role of the microbiota in experimental autoimmune encephalomyelitis, animal model of the disease, and several articles have been published in recent years about differences in intestinal micr...
Source: Medicina Clinica - Category: General Medicine Tags: Med Clin (Barc) Source Type: research
THURSDAY, Nov. 15, 2018 -- The rate and frequency of relapse vary for patients with multiple sclerosis (MS), and many report not visiting a health care provider during relapse, according to a study published in the November issue of Multiple...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Publication date: December 2018Source: The Lancet Neurology, Volume 17, Issue 12Author(s): Catherine Lubetzki
Source: The Lancet Neurology - Category: Neurology Source Type: research
No abstract available
Source: Neurology Today - Category: Neurology Tags: For Your Patients Source Type: research
No abstract available
Source: Neurology Today - Category: Neurology Tags: Disease Mechanisms Source Type: research
Task-specific training is an effective form of rehabilitation for improving mobility in neurological conditions. However, it remains unclear if task-specific training is effective in people with progressive disease.
Source: Physiotherapy - Category: Physiotherapy Authors: Tags: Systematic review Source Type: research
The aim of this study was to determine the association between walking ability in a clinical setting (activity capacity), walking ability in a person ’s daily environment (activity capability) and walking performance in daily life (activity performance), and the contribution of each activity construct to participation among people with multiple sclerosis (MS).
Source: Physiotherapy - Category: Physiotherapy Authors: Source Type: research
ConclusionWith the development of potent new medications, an increasing number of drugs are dangerous upon accidental exposure to toddlers and young children. The present 2018 list of documented fatal drugs has doubled compared with 2004, and special labeling of these medications is urgently needed to avoid such calamities.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Health | Multiple Sclerosis | Switzerland Health